Another example is that CRBN is highly expressed in breast invasive carcinoma (BRCA) in TCGA and breast cancer in HPA pathology, which aligned with in-trial PROTACs targeting estrogen receptor (ER) in breast cancer (NCT04072952; NCT05080842)1. Here, ESR1 is linked to invasive breast carcinoma.